Edition:
United Kingdom

People: GNI Group Ltd (2160.T)

2160.T on Tokyo Stock Exchange

2,906JPY
19 Jun 2019
Change (% chg)

¥104 (+3.71%)
Prev Close
¥2,802
Open
¥2,850
Day's High
¥2,938
Day's Low
¥2,847
Volume
207,200
Avg. Vol
190,813
52-wk High
¥5,180
52-wk Low
¥2,506

Luo, Ying 

Dr. Ying Luo has been serving as President, Representative Executive Officer, Chief Executive Officer and Director in GNI Group Ltd., as well as Chairman of the Board and CEO of two subsidiaries, Shanghai Genomics, Inc. and GNI-EPS Pharmaceuticals, Inc., and Chairman of the Board in another subsidiary, Beijing Continent Pharmaceutical Co., Ltd., since September 2011. He used to serve as Managing Director and Chief Operating Officer in the Company. He used to work for three other companies. He obtained his Doctor's degree in Science from University of Connecticut in 1991.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --